Switzerland-based NBE Therapeutics AG, a biopharmaceutical company, announced a $20 million extension of series B funding led by Novo Holdings. Earlier in the series B funding round, the company had received $20 million, bringing the total funding to $40 million. The Swiss startup will use the new funding for the testing of the anti-ROR1 antibody-drug conjugate (ADC) NBE-002 in patients with solid tumors.
The U.S, Based Array BioPharma received FDA approval for its much-awaited BRAFTOVI capsules with the combination of MEKTOVI tablets for the treatment of patients with metastatic melanoma with a BRAFV600E or BRAFV600K mutation.
RET-driven cancers include medullary and papillary thyroid cancer, non-small cell lung cancer, colorectal and bile duct cancer, which have been very difficult to treat till date. Chemotherapy has been the only available treatment but leads to multiple side effects.
To develop small molecules which can target RNA mis-splicing in neurological diseases, Celgene is launching a $60 million collaboration with Skyhawk Therapeutics. Celgene received the option to develop up to five drug molecules for correcting neurological diseases such as Huntington’s disease, amyotrophic lateral sclerosis etc. The $60 million payment includes milestones, license fees and royalties.
NBTXR3 is composed of crystalline nanoparticles to amplify the efficacy of radiation therapy. The idea is to administer NBTXR3 as intra-tumoral injections before external beam radiation therapy, thereby increasing the antitumor effect, and thus preparing the patient for surgical resection.
Last Friday, pharma giant AstraZeneca announced that it had received the go-ahead from the Drug Controller General of India (DCGI) to import and market durvalumab (ImfinziTM) in India. The receipt of this permission paves the way for the launch of durvalumab (ImfinziTM) in India. Durvalumab which is a patented drug of Astra-Zeneca, received permission in India to provide treatment for patients with unresectable non-small cell lung cancer and metastatic urothelial carcinoma.
The IPO has provided the biotech major with the financial bandwidth to aggressively pursue its new generation of CAR-T variants on a broader level, with the advancement of several therapies or the start of clinical trials over the next couple of months.
Previous research claimed that consumption of vitamin D rich foods can reduce the risk factors of colorectal cancer. There was no proper evidence available to link vitamin D levels and colorectal cancer. Now, new research led by the Harvard T.H. Chan School of Public Health, adds convincing evidence to authenticate the link.
On Wednesday, a day after Keytruda got the thumbs up for cervical cancer, the drug was approved for treatment of a rare form of non-Hodgkins lymphoma patients who cancer returned after at least two previous treatment lines. Last year, Keytruda also got an indication for classical Hodgkin lymphoma.
On Sunday, at the American Society of Clinical Oncology’s annual meeting, Novartis revealed the final outcome, showing that among patients with HR-positive, HER2-negative breast cancer, adding Kisqali to fulvestrant kept the disease away for eight months longer than fulvestrant alone.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.